Question Bank › Quietly replacing the old way

Quietly replacing the old way

Quietly replacing the old way: customers are switching to the company from an entrenched alternative, and the switching

Calls Tested
485
Answered YES
26
Hit Rate
5.4%
rare by design

Amgen Inc. (AMGN) — this company's answers

NO on the Q3 2018 call 2018-10-30 B+
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes customers switching from an entrenched alternative to their product, and that this switching is still in early stages with most potential switchers not yet converted. Key points from transcript: - Aimovig launch: "over 100,000 patients starting Aimovig since launch" and "first mover advantage" but also "aided awareness among patients for whom Aimovig would be appropriate still remains low at just above 10%." This suggests that many potential patients are not yet aware, so switching is early. But is there an entrenched alternative? Migraine prevention previously had no specific therapy? The transcript says "People suffering from migraine and their physicians have been waiting for years for an effective new therapy" implying there was no established alternative. So it's not switching from an incumbent; it's new therapy for unmet need. That might not be "switching" from an entrenched alternative. - Repatha: "we've made strong progress to improve patient access" and "lower out-of-pocket costs" but that's about access, not switching from another product. They mention "leading share in the PCSK9 class" but that's within class, not displacing an alternative. - Prolia: "share gains in both the U.S. and internationally" - that could be switching from other osteoporosis treatments? But not explicitly described as displacing an entrenched alternative. - Biosimilars: They are launching biosimilars to Herceptin and Humira, which are entrenched alternatives. But the transcript says "we're excited to have launched KANJINTI, a biosimilar version of Herceptin, and earlier this month we launched AMGEVITA, Amgen's biosimilar to Humira." That is switching from the originator to biosimilar. But is it early? They say "we have eight additional biosimilar programs" and "we expect this business to be an important growth driver." However, they don't explicitly say that most of the market has not yet switched. They mention "we've done quite well through a series of tender processes" but not that it's early.

← Back to the full AMGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON — abandoning or displacing an incumbent supplier, a legacy product or technology, an older method, or an established way of doing things in order to adopt what this company sells — AND does management convey that this switching is still in its early stages, with most of the potential switchers not yet converted? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon as a present-tense reality: a substitution is underway in the company's market, and this company is the one being substituted IN. Any genuine expression of this counts, and the form varies widely across industries. For example — management describing customers replacing a competitor's or incumbent's product with theirs; customers moving off a legacy technology, material, method, platform, or practice onto the company's; buyers who used to do the work themselves, or do without, now adopting the company's offering instead; customers consolidating onto the company after dropping other vendors; management noting that wins are coming at the direct expense of a named or clearly implied alternative that used to be the default; or management describing that the conversation in its market has shifted from "whether to switch" to "how fast to switch." Two things should come through in management's own voice. First, THE SWITCHING IS ACTUALLY HAPPENING NOW — real customers who have already moved, described as a recurring pattern in current business (won accounts, displaced incumbents, conversions completed, replacements underway), not a hope that switching will someday begin. Second, THE INSTALLED BASE OF THE OLD WAY IS STILL LARGE — management conveys, directly or plainly in substance, that what has switched so far is small relative to what is still out there using the old alternative, so the substitution has substantial distance left to run. Answer NO if management simply reports strong demand, a good quarter, or growth in a market with no incumbent or prior alternative being displaced. NO if the switching is only anticipated, targeted, or described as a future opportunity rather than already occurring. NO if the only evidence is one isolated account win with no sense of a broader substitution pattern. NO if the displacement described is essentially complete, with the old alternative already largely gone. NO if the switching is driven by a one-time event — a single competitor's collapse, a temporary shortage, a forced recall — that management expects to normalize rather than an ongoing substitution. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
NICE NICE Ltd. Q4 2023 2024-02-22 B+
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
IMAX IMAX Corporation Q2 2023 2023-07-26 B+
PFIE Profire Energy, Inc. Q1 2023 2023-05-13 B
TOST Toast, Inc. Q4 2022 2023-02-16 C+
BLZE Backblaze, Inc. Q3 2022 2022-11-11 D
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
BIG Big Lots, Inc. Q1 2022 2022-05-27 F
FLYW Flywire Corporation Q1 2022 2022-05-14 B+
ZVIA Zevia PBC Q1 2022 2022-05-12 B
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
RELY Remitly Global, Inc. Q4 2021 2022-03-02 B
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
RNW ReNew Energy Global Plc Q2 2022 2021-11-18 C
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
INST Instructure's Q4 2017 2018-02-12 B+
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
BLKB Blackbaud, Inc. Q1 2017 2017-05-02 B+
EVBN Evans Bancorp, Inc. Q4 2016 2017-02-06 B+
BDC Belden Inc. Q4 2016 2017-02-02 B

How the model reasoned

BLKB · Q1 2017 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES Management describes customers switching from entrenched alternatives (legacy hardware systems, older Raiser's Edge versions, standalone point solutions) to Blackbaud's cloud solutions like NXT, with examples of recent replacements and migrations already occurring. They also note that much of the potential remains, as the installed base of legacy methods is still large 25% of subscription revenue, and they describe the opportunity as "really early days" with substantial distance left to run. This fits the criteria of a present-tense substitution pattern in the market, not just future hope. The high retention on their own base (93%) combined with declining maintenance revenue shows the shift is active and ongoing, while new wins against competitors and legacy alternatives are happening now. The TAM of $7 billion with hundreds of thousands of addressable customers reinforces that switching is early-stage relative to the total opportunity. The answer is YES. The question is answered with YES. The question is answered with YES.
BLZE · Q3 2022 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing current customer switches from entrenched alternatives (AWS for urlscan.io; Synology NAS/on-prem for Fiture; broader AWS and on-prem users), with these as real, ongoing patterns. They explicitly note that much of the potential remains ("so much of the world's data is still on-premises" and "customers that are inside of AWS and others"), confirming the substitution is early-stage relative to the large installed base. This is conveyed directly in Gleb's responses as a present-tense reality, not merely anticipated. The two examples plus the broader opportunity framing establish a coherent substitution underway, with the company being substituted in. The investor question on percentages and Gleb's reply reinforce the pattern without contradicting the current movement. No single-event or future-only framing applies here. Thus, both conditions are met.
APPS · Q1 2024 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing customers shifting from Apple/Google app stores to DT Hub and SingleTap-enabled alternative distribution as an ongoing, early-stage substitution. Bill Stone notes the company has already launched DT Hub with four U.S. operators and is generating revenue today, while highlighting "increasing pressure on the duopoly" and 5 monetization ways for SingleTap that enable publishers to direct-download apps outside traditional stores. He explicitly calls it "very early days and not yet material to our overall results" and "early innings," confirming the installed base of the old way remains large and the switch is just beginning with incremental RPD gains from devices engaging the new platform. This meets the criteria of a present-tense substitution underway, with the company positioned as the alternative being adopted.

More from the question bank

Personal bests piling upSomebody else pays firstReady-to-run scale already paid for and now Earned edge, pressed harderStrong facts, held-back storyInformed outsiders doubling downAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.